University Medical Center Utrecht owns and operates hospitals in the Netherlands. The company focuses on the areas of brain, infection and immunity, circulatory health, personalized cancer care, regenerative medicine and stem cells, and child health. It offers healthcare services in the areas of imaging, biomedical genetics, heart and lungs, surgical specialties, brain, internal medicine and dermatology, pediatrics, laboratories and pharmacy, anesthesiology, intensive care, emergency medicine, and woman and baby. The company also provides healthcare programs and training to students, doctors, researchers, and other healthcare providers. University Medical Center Utrecht is based in Utrecht, ...
Utrecht, 3584 CX
Stand Up to Cancer, Dutch Cancer Society, American Association for Cancer Research, Hubrecht Institute, University Medical Center Utrecht, Netherlands Cancer Institute, and Wellcome Trust Sanger Institute Announce Formation of Dream Team
Nov 12 13
Stand Up To Cancer (SU2C) and the Dutch Cancer Society (KWF Kankerbestrijding), along with the American Association for Cancer Research (AACR), SU2Cs scientific partner, announced the formation of a Dream Team dedicated to developing new tools and technologies for preclinical drug testing and analysis. The Sta Op Tegen Kanker (Stand Up To Cancer) Dream Team Translational Cancer Research Grant will provide EUR 6 million ($8.1 million, at the current conversion rate) in funding over four years for this project that will establish a novel, genetically diverse living biobank of patients tumor samples that are maintained and grown in a laboratory, using technology developed by this Dream Team. Called tumor organoids, these growing tumors provide an unprecedented opportunity to investigate the DNA changes that have occurred in these tumors and the consequences of those changes. Importantly, these tumor organoids also will allow researchers to conduct studies of sensitivity and resistance to a large number of anticancer drugs in a laboratory, laying the groundwork for more sophisticated clinical trials that will test treatment regimens specific to the genetic profiles of individual patients and their tumors. Researchers on this Dream Team represent four institutions: the Hubrecht Institute, the University Medical Center Utrecht, the Netherlands Cancer Institute, and the Wellcome Trust Sanger Institute. This Dream Team unites researchers across Europe in a concerted effort to use a groundbreaking new technology to rapidly analyze novel treatment modalities. Hans Clevers, M.D., Ph.D., will lead the Dream Team. Johannes Bos, Ph.D., is the co-leader of the project, which is titled Tumor Organoids: A New Preclinical Model for Drug Sensitivity Analysis.